

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Oxfendazole / Oxclozanide Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, Testis, Brain)
repeated exposure

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0	Revision Date: 2025/04/14	SDS Number: 7942510-00010	Date of last issue: 2024/09/28 Date of first issue: 2021/03/19
----------------	------------------------------	------------------------------	---

H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

: Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P391 Collect spillage.

: Storage:

P405 Store locked up.

: Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed : Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
oxclozanide	2277-92-1	>= 40 - < 50	9-1297
oxfendazole	53716-50-0	>= 20 - < 25	-
Starch, oxidized	65996-62-5	>= 10 - < 20	8-99
Magnesium stearate	557-04-0	>= 1 - < 10	2-611

4. FIRST AID MEASURES

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation

: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling

: Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14

SDS Number: 7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

practice, based on the results of the workplace exposure assessment

Keep container tightly closed.

Minimize dust generation and accumulation.

Keep container closed when not in use.

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the environment.

: Oxidizing agents

: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Avoidance of contact
Hygiene measures

Storage

Conditions for safe storage

: Keep in properly labelled containers.
Store locked up.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid

: Do not store with the following product types:
Strong oxidizing agents

Packaging material

: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Concentra- tion standard / Permissible con- centration	Basis
oxclozanide	2277-92-1	TWA	0.4 mg/m ³ (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Starch, oxidized	65996-62-5	TWA (inhal- able dust)	0.5 mg/m ³	ACGIH
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m ³	ACGIH
		TWA (Res- pirable par- ticle)	3 mg/m ³	ACGIH

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

		ticulate mat- ter)	
--	--	-----------------------	--

Engineering measures	: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
Personal protective equipment	
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: powder
Colour	: white to off-white, light cream, cream
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Boiling point, initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Flammability (liquids)	: Not applicable
Lower explosion limit and upper explosion limit / flammability limit	
Upper explosion limit / Up- per flammability limit	: No data available
Lower explosion limit /	: No data available
Lower flammability limit	
Flash point	: Not applicable
Decomposition temperature	: No data available
pH	: No data available
Evaporation rate	: Not applicable
Auto-ignition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n- octanol/water	: Not applicable
Vapour pressure	: Not applicable
Density and / or relative density	
Relative density	: No data available
Density	: 0.88 g/cm ³
Relative vapour density	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available

10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reac- tions	: May form explosive dust-air mixture during processing, han- dling or other means.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Can react with strong oxidizing agents.

Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials Hazardous decomposition products	: Oxidizing agents : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

oxyclozanide:

Acute oral toxicity	: LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	: LDLo (sheep): 10 mg/kg Application Route: Intravenous

oxfendazole:

Acute oral toxicity	: LD50 (Rat): > 6,000 mg/kg LD50 (Dog): 1,600 mg/kg LD50 (sheep): 250 mg/kg
---------------------	---

Magnesium stearate:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

oxyclozanide:

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

||| Remarks : Not classified due to lack of data.

oxfendazole:

||| Species : Rabbit
||| Result : No skin irritation

Magnesium stearate:

||| Species : Rabbit
||| Result : No skin irritation
||| Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

oxclozanide:

||| Remarks : Not classified due to lack of data.

oxfendazole:

||| Species : Rabbit
||| Result : No eye irritation

Magnesium stearate:

||| Species : Rabbit
||| Result : No eye irritation
||| Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

oxclozanide:

||| Exposure routes : Dermal
||| Remarks : Not classified due to lack of data.

Magnesium stearate:

||| Test Type : Maximisation Test
||| Exposure routes : Skin contact
||| Species : Guinea pig
||| Method : OECD Test Guideline 406
||| Result : negative

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

||| Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

oxclozanide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Test Type: Mouse Lymphoma
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Oral
Result: positive

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

oxclozanide:

||| Remarks : Not classified due to lack of data.

oxfendazole:

||| Species : Rat
Application Route : Oral
Exposure time : 1 Years
Symptoms : No adverse effects
Target Organs : Liver

||| Species : Rat
Application Route : Oral
Exposure time : 2 Years
Symptoms : No adverse effects
Target Organs : Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

oxclozanide:

||| Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development

: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment

: Suspected of damaging the unborn child.

oxfendazole:

Effects on fertility

: Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 17 mg/kg body weight
Target Organs: Testes
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.9 mg/kg body weight
Target Organs: Liver
Result: No effects on fertility

Test Type: Fertility
Species: Mouse
Application Route: Oral
Duration of Single Treatment: 1 Months

Oxfendazole / Oxclozanide FormulationVersion
9.0Revision Date:
2025/04/14SDS Number:
7942510-00010Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

		Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects
		Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
Magnesium stearate:		
Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Oxfendazole / Oxclozanide FormulationVersion
9.0Revision Date:
2025/04/14SDS Number:
7942510-00010Date of last issue: 2024/09/28
Date of first issue: 2021/03/19**Components:****oxyclozanide:**

Exposure routes	:	Oral
Target Organs	:	Central nervous system
Assessment	:	May cause damage to organs.

STOT - repeated exposure

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Components:**oxyclozanide:**

Target Organs	:	Brain, Liver
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Exposure routes	:	Oral
Target Organs	:	Liver, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****oxyclozanide:**

Species	:	Rat
NOAEL	:	9 mg/kg
LOAEL	:	44.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects

Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

oxfendazole:

Species	:	Rat
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Species	:	Rat
NOAEL	:	3.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis
Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Liver
Species	:	Mouse
NOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver
Species	:	Dog
NOAEL	:	6 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported
Species	:	Dog
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Lymph nodes, thymus gland
Species	:	Dog
NOAEL	:	13.5 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Liver
Starch, oxidized:		
Species	:	Rat
NOAEL	:	22,500 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Magnesium stearate:		
Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Aspiration toxicity

Not classified based on available information.

Components:

oxyclozanide:

|| Not applicable

Experience with human exposure

Components:

oxyclozanide:

|| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

oxyclozanide:

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

|| M-Factor (Acute aquatic toxicity) : 1

|| M-Factor (Chronic aquatic toxicity) : 1

oxfendazole:

|| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l
Exposure time: 96 h

|| LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l
Exposure time: 96 h

|| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

|| Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

|| NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity) : 1

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

oxclozanide:

Stability in water : Hydrolysis: 50 %(156 d)
Method: OECD Test Guideline 111

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

oxfendazole:

Stability in water : Hydrolysis: < 5 %(4 d)

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

oxclozanide:

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

oxfendazole:

Partition coefficient: n-octanol/water : log Pow: 1.95

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

oxclozanide:

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(oxfendazole, oxclozanide)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(oxfendazole, oxclozanide)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>=1 - <10	-

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
Magnesium stearate	-

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version 9.0 Revision Date: 2025/04/14 SDS Number: 7942510-00010 Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.

SAFETY DATA SHEET



Oxfendazole / Oxclozanide Formulation

Version
9.0

Revision Date:
2025/04/14

SDS Number:
7942510-00010

Date of last issue: 2024/09/28
Date of first issue: 2021/03/19

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN